Turk Kardiyol Dern Ars. Ahead of Print: TKDA-82830 | DOI: 10.5543/tkda.2018.82830
Safety of radial coronary angiography with uninterrupted direct-acting oral anticoagulant treatment
Tuğba Kemaloğlu Öz1
, Tayfun Gürol1
, Nedim Umutay Sarıgül2
, Utku Aslan1
, Maryam Kobegenova1
, Alper Aydın1
, Özer Soylu1
, Bahadır Dağdeviren11
Bahçeşehir University, Cardiology Department, İstanbul, Turkey.2
Kardio Bremen, Cardiology Department, Bremen, Germany.
Background and AIM It is not known whether direct-acting oral anticoagulants (DOACs), including dabigatran, apixaban and rivaroxaban, increase the risk of bleeding complications during and after coronary catheterization. The aim of this study was to investigate the safety of uninterrupted DOAC treatment during diagnostic radial coronary angiography (CAG).Keywords:
METHODS This study that included 160 patients undergoing diagnostic radial cardiac catheterization. 60 of them who were using one of the DOACs (apixaban, rivaroxaban or dabigatran) were enrolled in a group A. Post-procedure results from patients in group A were compared with those of a age and sex matched control group (group B) that included 100 patients undergoing radial CAG who did not use DOACs.
RESULTS There was no significant difference in the procedure and compression times, creatinine levels, gender, hypertension, diabetes mellitus, smoking, alcohol use, vascular disease or congestive heart failure between the two groups. During the one-month follow-up period, only one radial occlusion was registered in the control group (group B). There was no case of a large hematoma (> 5 cm or extended to the forearm), dissection, fistula, perforation or compartment syndrome. Hematomas smaller than 5 cm were seen in two patients (one in each group). No thrombotic events were seen during follow-up examinations.
CONCLUSION Performing radial CAG with uninterrupted DOAC treatment appears to carry no risk of increased early- or short-term complications. The simple uninterrupted DOAC strategy is comfortable, easy and safe.
Anticoagulants, apixaban, coronary angiography, dabigatran, radial artery, rivaroxaban.
How to cite this article
Corresponding Author: Tuğba Kemaloğlu Öz, Türkiye